{
  "pmcid": "10638529",
  "abstract": "250-word version:\n\nTitle: Randomised Controlled Trial of Autofluorescence in Thyroidectomy\n\nBackground: This multicentre randomised controlled trial evaluated the use of Fluobeam速 LX for parathyroid gland visualization during total thyroidectomy to reduce postoperative hypoparathyroidism.\n\nMethods: Conducted in four European centres, patients aged over 18 years undergoing total thyroidectomy were randomised 1:1 to either the intervention group using Fluobeam速 LX or a control group without it. The primary outcome was the rate of low parathyroid hormone (PTH) levels on the first postoperative day. Randomisation was performed using the Eurocrine速 platform with allocation concealed from patients. The study was single-blinded.\n\nResults: Between January 2021 and August 2022, 535 patients were randomised, and 486 were analysed (246 intervention, 240 control). The rate of low PTH levels was 26.0% in the intervention group and 32.1% in the control group (RR 0.81, 95% CI 0.61 to 1.07; p = 0.141). In a subgroup undergoing central lymph node dissection, the rates were 18.3% and 33.7%, respectively (RR 0.54, 95% CI 0.31 to 0.93; p = 0.021). No specific harm related to Fluobeam速 LX was reported.\n\nInterpretation: Autofluorescence did not significantly reduce low PTH rates in the overall cohort but was beneficial in a subgroup. Trial registration: NCT04509011. Funding: Not specified.",
  "word_count": 203
}